BsmI polymorphism of vitamin D receptor gene and cancer risk: A comprehensive meta-analysis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 769, Issue , 2014, Pages 17-34

  Raimondi, Sara ^a   Pasquali, Elena ^a   Gnagnarella, Patrizia ^a   Serrano, Davide ^a   Disalvatore, Davide ^a   Johansson, Harriet A ^a   Gandini, Sara ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

BsmI; Meta analysis; Molecular epidemiology; VDR; Vitamin D

Indexed keywords

VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ENDODEOXYRIBONUCLEASE BSMI; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ARTICLE; BRAIN CANCER; BREAST CANCER; BSMI GENE; CANCER LOCALIZATION; CANCER RISK; CAUCASIAN; COLORECTAL CANCER; DISEASE ASSOCIATION; ESOPHAGEAL ADENOCARCINOMA; ETHNICITY; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; MOUTH SQUAMOUS CELL CARCINOMA; NASOPHARYNX CARCINOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; SIGNAL TRANSDUCTION; VITAMIN D RECEPTOR GENE; CASE CONTROL STUDY; ETHNIC GROUP; ETHNOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; META ANALYSIS; METABOLISM; NEOPLASMS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SKIN NEOPLASMS; STATISTICS AND NUMERICAL DATA; ETHNIC DIFFERENCE; SKIN CANCER;

CASE-CONTROL STUDIES; DEOXYRIBONUCLEASES, TYPE II SITE-SPECIFIC; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASMS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, CALCITRIOL; RISK FACTORS; SKIN NEOPLASMS;

EID: 84904736040     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2014.06.001     Document Type: Article

References (130)

1. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., Colditz G.A., Willett W.C., Hankinson S.E. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1991-1997.
2. Lowe L.C., Guy M., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Colston K.W. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer 2005, 41:1164-1169.
3. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., Holick M.F. The role of vitamin D in cancer prevention. Am. J. Public Health 2006, 96:252-261.
4. Giovannucci E. Epidemiological evidence for vitamin D and colorectal cancer. J. Bone Miner. Res. 2007, 22(Suppl. 2):V81-V85.
5. Gorham E.D., Garland C.F., Garland F.C., Grant W.B., Mohr S.B., Lipkin M., Newmark H.L., Giovannucci E., Wei M., Holick M.F. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am. J. Prev. Med. 2007, 32:210-216.
6. Spina C.S., Ton L., Yao M., Maehr H., Wolfe M.M., Uskokovic M., Adorini L., Holick M.F. Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J. Steroid Biochem. Mol. Biol. 2007, 103:757-762.
7. Abbas S., Linseisen J., Slanger T., Kropp S., Mutschelknauss E.J., Flesch-Janys D., Chang-Claude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008, 29:93-99.
8. Chen P., Hu P., Xie D., Qin Y., Wang F., Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 2010, 121:469-477.
9. Touvier M., Chan D.S., Lau R., Aune D., Vieira R., Greenwood D.C., Kampman E., Riboli E., Hercberg S., Norat T. Meta-analyses of vitamin D intake 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1003-1016.
10. Fedirko V., Riboli E., Tjonneland A., Ferrari P., Olsen A., Bueno-de-Mesquita H.B., van Duijnhoven F.J., Norat T., Jansen E.H., Dahm C.C., Overvad K., Boutron-Ruault M.C., Clavel-Chapelon F., Racine A., Lukanova A., Teucher B., Boeing H., Aleksandrova K., Trichopoulou A., Benetou V., Trichopoulos D., Grioni S., Vineis P., Panico S., Palli D., Tumino R., Siersema P.D., Peeters P.H., Skeie G., Brustad M., Chirlaque M.D., Barricarte A., Ramon Quiros J., Sanchez M.J., Dorronsoro M., Bonet C., Palmqvist R., Hallmans G., Key T.J., Crowe F., Khaw K.T., Wareham N., Romieu I., McKay J., Wark P.A., Romaguera D., Jenab M. Prediagnostic 25-hydroxyvitamin D, VDR and CASR polymorphisms, and survival in patients with colorectal cancer in western European populations. Cancer Epidemiol. Biomarkers Prev. 2012, 21:582-593.
11. Bauer S.R., Hankinson S.E., Bertone-Johnson E.R., Ding E.L. Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore) 2013, 92:123-131.
12. James S.Y., Williams M.A., Kelsey S.M., Newland A.C., Colston K.W. The role of vitamin D derivatives and retinoids in the differentiation of human leukaemia cells. Biochem. Pharmacol. 1997, 54:625-634.
13. Colston K., Colston M.J., Feldman D. 1,25-Dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 1981, 108:1083-1086.
14. Lointier P., Wargovich M.J., Saez S., Levin B., Wildrick D.M., Boman B.M. The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res. 1987, 7:817-821.
15. Bostick R.M., Goodman M., Sidelnikov E. Calcium and vitamin D. Genetics of Colorectal Cancer 2009, 277-296. Springer Science+Business Media, LCC, New York, NY. J.D. Potter, N.M. Lindor (Eds.).
16. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 1998, 13:325-349.
17. Manolagas S.C., Yu X.P., Girasole G., Bellido T. Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin. Nephrol. 1994, 14:129-143.
18. Holick C.N., Stanford J.L., Kwon E.M., Ostrander E.A., Nejentsev S., Peters U. Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1990-1999.
19. Eisman J.A., Barkla D.H., Tutton P.J. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. Cancer Res. 1987, 47:21-25.
20. Evans S.R., Houghton A.M., Schumaker L., Brenner R.V., Buras R.R., Davoodi F., Nauta R.J., Shabahang M. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. J. Surg. Res. 1996, 61:127-133.
21. Hansen C.M., Madsen M.W., Arensbak B., Skak-Nielsen T., Latini S., Binderup L. Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes. Commun. 1998, 5:109-120.
22. Yudoh K., Matsuno H., Kimura T. 1alpha 25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J. Lab. Clin. Med. 1999, 133:120-128.
23. Osborne J.E., Hutchinson P.E. Vitamin D and systemic cancer: is this relevant to malignant melanoma?. Br. J. Dermatol. 2002, 147:197-213.
24. Newton-Bishop J.A., Beswick S., Randerson-Moor J., Chang Y.M., Affleck P., Elliott F., Chan M., Leake S., Karpavicius B., Haynes S., Kukalizch K., Whitaker L., Jackson S., Gerry E., Nolan C., Bertram C., Marsden J., Elder D.E., Barrett J.H., Bishop D.T. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J. Clin. Oncol. 2009, 27:5439-5444.
25. Chen Y., Liu W., Sun T., Huang Y., Wang Y., Deb D.K., Yoon D., Kong J., Thadhani R., Li Y.C. 1,25-Dihydroxyvitamin D promotes negative feedback regulation of TLR signaling via targeting microRNA-155-SOCS1 in macrophages. J. Immunol. 2013, 190:3687-3695.
26. Fu B., Wang H., Wang J., Barouhas I., Liu W., Shuboy A., Bushinsky D.A., Zhou D., Favus M.J. Epigenetic regulation of BMP2 by 1,25-dihydroxyvitamin D3 through DNA methylation and histone modification. PLoS One 2013, 8:e61423.
27. Uitterlinden A.G., Fang Y., van Meurs J.B., van Leeuwen H., Pols H.A. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J. Steroid Biochem. Mol. Biol. 2004, 89-90:187-193.
28. Morrison N.A., Yeoman R., Kelly P.J., Eisman J.A. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:6665-6669.
29. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
30. Daya-Grosjean L., Sarasin A. The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. Mutat. Res. 2005, 571:43-56.
31. Ellison T.I., Smith M.K., Gilliam A.C., MacDonald P.N. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J. Invest. Dermatol. 2008, 128:2508-2517.
32. Teichert A.E., Elalieh H., Elias P.M., Welsh J., Bikle D.D. Overexpression of hedgehog signaling is associated with epidermal tumor formation in vitamin D receptor-null mice. J. Invest. Dermatol. 2011, 131:2289-2297.
33. Ingles S.A., Haile R.W., Henderson B.E., Kolonel L.N., Nakaichi G., Shi C.Y., Yu M.C., Ross R.K., Coetzee G.A. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol. Biomarkers Prev. 1997, 6:93-98.
34. Slatter M.L., Yakumo K., Hoffman M., Neuhausen S. Variants of the VDR gene and risk of colon cancer (United States). Cancer Causes Control 2001, 12:359-364.
35. Gandini S., Raimondi S., Gnagnarella P., Dore J.F., Maisonneuve P., Testori A. Vitamin D and skin cancer: a meta-analysis. Eur. J. Cancer 2009, 45:634-641.
36. Bai Y.H., Lu H., Hong D., Lin C.C., Yu Z., Chen B.C. Vitamin D receptor gene polymorphisms and colorectal cancer risk: a systematic meta-analysis. World J. Gastroenterol. 2012, 18:1672-1679.
37. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7:684-700.
38. Guo Z., Wen J., Kan Q., Huang S., Liu X., Sun N., Li Z. Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumour Biol. 2013.
39. Liu Y., Li C., Chen P., Li X., Li M., Guo H., Li J., Chu R., Wang H. Polymorphisms in the vitamin D receptor (VDR) and the risk of ovarian cancer: a meta-analysis. PLoS One 2013, 8:e66716.
40. Qin X., Lu Y., Qin A., Chen Z., Peng Q., Deng Y., Xie L., Wang J., Li R., Zeng J., Li S., Zhao J. Vitamin D receptor bsmcapital I, Ukrainian polymorphism and ovarian cancer risk: a meta-analysis. Int. J. Gynecol. Cancer 2013, 23:1178-1183.
41. Wang J., He Q., Shao Y.G., Ji M., Bao W. Associations between vitamin D receptor polymorphisms and breast cancer risk. Tumour Biol. 2013.
42. Zhang Y., Tong S.C., Guan L.H., Na F., Zhao W., Wei L. Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer. Tumour Biol. 2013.
43. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A., Thacker S.B. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
44. Latoch E.J., Panasiuk A., Muszynska-Roslan K., Krawczuk-Rybak M., Galicka A. Fokl and bsml gene polymorphisms of vitamin D receptor in children and young adults with neoplastic disease from north-eastern region of Poland. Pol. Merkur Lekarski. 2010, 28:362-365.
45. van Houwelingen H.C., Arends L.R., Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat. Med. 2002, 21:589-624.
46. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21:1539-1558.
47. http://hapmap.ncbi.nlm.nih.gov/.
48. Macaskill P., Walter S.D., Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat. Med. 2001, 20:641-654.
49. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005, 289:F8-F28.
50. Bretherton-Watt D., Given-Wilson R., Mansi J.L., Thomas V., Carter N., Colston K.W. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br. J. Cancer 2001, 85:171-175.
51. Ma J., Stampfer M.J., Gann P.H., Hough H.L., Giovannucci E., Kelsey K.T., Hennekens C.H., Hunter D.J. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in united states physicians. Cancer Epidemiol. Biomarkers Prev. 1998, 7:385-390.
52. Gandini S., Boniol M., Haukka J., Byrnes G., Cox B., Sneyd M.J., Mullie P., Autier P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 2011, 128:1414-1424.
53. Autier P., Gandini S., Mullie P. A systematic review: influence of vitamin D supplementation on serum 25-hydroxyvitamin D concentration. J. Clin. Endocrinol. Metab. 2012, 97:2606-2613.
54. Szendroi A., Speer G., Tabak A., Kosa J.P., Nyirady P., Majoros A., Romics I., Lakatos P. The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer. Can. J. Urol. 2011, 18:5710-5716.
55. Chen L., Davey Smith G., Evans D.M., Cox A., Lawlor D.A., Donovan J., Yuan W., Day I.N., Martin R.M., Lane A., Rodriguez S., Davis M., Zuccolo L., Collin S.M., Hamdy F., Neal D., Lewis S.J. Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2874-2881.
56. Orlow I., Roy P., Reiner A.S., Yoo S., Patel H., Paine S., Armstrong B.K., Kricker A., Marrett L.D., Millikan R.C., Thomas N.E., Gruber S.B., Anton-Culver H., Rosso S., Gallagher R.P., Dwyer T., Kanetsky P.A., Busam K., From L., Begg C.B., Berwick M. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int. J. Cancer 2012, 130:405-418. GEM Study Group.
57. Jenab M., McKay J., Bueno-de-Mesquita H.B., van Duijnhoven F.J., Ferrari P., Slimani N., Jansen E.H., Pischon T., Rinaldi S., Tjonneland A., Olsen A., Overvad K., Boutron-Ruault M.C., Clavel-Chapelon F., Engel P., Kaaks R., Linseisen J., Boeing H., Fisher E., Trichopoulou A., Dilis V., Oustoglou E., Berrino F., Vineis P., Mattiello A., Masala G., Tumino R., Vrieling A., van Gils C.H., Peeters P.H., Brustad M., Lund E., Chirlaque M.D., Barricarte A., Suarez L.R., Molina E., Dorronsoro M., Sala N., Hallmans G., Palmqvist R., Roddam A., Key T.J., Khaw K.T., Bingham S., Boffetta P., Autier P., Byrnes G., Norat T., Riboli E. Vitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations. Cancer Epidemiol. Biomarkers Prev. 2009, 18:2485-2491.
58. Tang C., Chen N., Wu M., Yuan H., Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009, 117:391-399.
59. Thill M., Fischer D., Kelling K., Hoellen F., Dittmer C., Hornemann A., Salehin D., Diedrich K., Friedrich M., Becker S. Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J. Steroid Biochem. Mol. Biol. 2010, 121:387-390.
60. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., Wu-Wong.J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 2006, 57:234-240.
61. Lauridsen A.L., Vestergaard P., Hermann A.P., Brot C., Heickendorff L., Mosekilde L., Nexo E. Plasma concentrations of 25-hydroxy-vitamin D and 1,25-dihydroxy-vitamin D are related to the phenotype of gc (vitamin D-binding protein): a cross-sectional study on 595 early postmenopausal women. Calcif. Tissue Int. 2005, 77:15-22.
62. Ingles S.A., Coetzee G.A., Ross R.K., Henderson B.E., Kolonel L.N., Crocitto L., Wang W., Haile R.W. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans. Cancer Res. 1998, 58:1620-1623.
63. Habuchi T., Suzuki T., Sasaki R., Wang L., Sato K., Satoh S., Akao T., Tsuchiya N., Shimoda N., Wada Y., Koizumi A., Chihara J., Ogawa O., Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000, 60:305-308.
64. Chokkalingam A.P., McGlynn K.A., Gao Y.T., Pollak M., Deng J., Sesterhenn I.A., Mostofi F.K., Fraumeni J.F., Hsing A.W. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2001, 61:4333-4336.
65. Liu J.H., Li H.W., Wang J.Q., Li M., Xin D.Q., Na X., Zhang M., Ye S.Y., Na Y.Q. Vitamin D receptor gene bsm I polymorphism and the susceptibility to prostate cancer in northern Chinese Han population. Zhonghua Nan Ke Xue 2003, 9:413-416.
66. Nam R.K., Zhang W.W., Trachtenberg J., Jewett M.A., Emami M., Vesprini D., Chu W., Ho M., Sweet J., Evans A., Toi A., Pollak M., Narod S.A. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2003, 12:1429-1437.
67. Suzuki K., Matsui H., Ohtake N., Nakata S., Takei T., Koike H., Nakazato H., Okugi H., Hasumi M., Fukabori Y., Kurokawa K., Yamanaka H. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int. J. Urol. 2003, 10:261-266.
68. Huang S.P., Chou Y.H., Wayne Chang W.S., Wu M.T., Chen Y.Y., Yu C.C., Wu T.T., Lee Y.H., Huang J.K., Wu W.J., Huang C.H. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett. 2004, 207:69-77.
69. Oakley-Girvan I., Feldman D., Eccleshall T.R., Gallagher R.P., Wu A.H., Kolonel L.N., Halpern J., Balise R.R., West D.W., Paffenbarger R.S., Whittemore A.S. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1325-1330.
70. Hayes V.M., Severi G., Padilla E.J., Eggleton S.A., Southey M.C., Sutherland R.L., Hopper J.L., Giles G.G. Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14:997-999.
71. Chaimuangraj S., Thammachoti R., Ongphiphadhanakul B., Thammavit W. Lack of association of VDR polymorphisms with Thai prostate cancer as compared with benign prostate hyperplasia and controls. Asian Pac. J. Cancer Prev. 2006, 7:136-139.
72. Cicek M.S., Liu X., Schumacher F.R., Casey G., Witte J.S. Vitamin D receptor genotypes/haplotypes and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2549-2552.
73. Li H., Stampfer M.J., Hollis J.B., Mucci L.A., Gaziano J.M., Hunter D., Giovannucci E.L., Ma J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007, 4:e103.
74. Mikhak B., Hunter D.J., Spiegelman D., Platz E.A., Hollis B.W., Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 2007, 67:911-923.
75. Onen I.H., Ekmekci A., Eroglu M., Konac E., Yesil S., Biri H. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer. Exp. Biol. Med. (Maywood) 2008, 233:1608-1614.
76. Bai Y., Yu Y., Yu B., Ge J., Ji J., Lu H., Wei J., Weng Z., Tao Z., Lu J. Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the han population of southern china. BMC Med. Genet. 2009, 10. 125-2350-10-125.
77. Holt S.K., Kwon E.M., Peters U., Ostrander E.A., Stanford J.L. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2009, 18:1929-1933.
78. Ruggiero M., Pacini S., Aterini S., Fallai C., Ruggiero C., Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol. Res. 1998, 10:43-46.
79. Hou M.F., Tien Y.C., Lin G.T., Chen C.J., Liu C.S., Lin S.Y., Huang T.J. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res. Treat. 2002, 74:1-7.
80. Buyru N., Tezol A., Yosunkaya-Fenerci E., Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. Exp. Mol. Med. 2003, 35:550-555.
81. Guy M., Lowe L.C., Bretherton-Watt D., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Thomas V., Colston K.W. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin. Cancer Res. 2004, 10:5472-5481.
82. Hefler L.A., Tempfer C.B., Grimm C., Lebrecht A., Ulbrich E., Heinze G., Leodolter S., Schneeberger C., Mueller M.W., Muendlein A., Koelbl H. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004, 101:264-269.
83. VandeVord P.J., Wooley P.H., Darga L.L., Severson R.K., Wu B., Nelson D.A. Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women. Breast Cancer Res. Treat. 2006, 100:103-107.
84. Trabert B., Malone K.E., Daling J.R., Doody D.R., Bernstein L., Ursin G., Marchbanks P.A., Strom B.L., Humphrey M.C., Ostrander E.A. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res. 2007, 9:R84.
85. Sinotte M., Rousseau F., Ayotte P., Dewailly E., Diorio C., Giguere Y., Berube S., Brisson J. Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population. Endocr. Relat. Cancer. 2008, 15:975-983.
86. Gapska P., Scott R.J., Serrano-Fernandez P., Huzarski T., Byrski T., Kladny J., Gronwald J., Gorski B., Cybulski C., Lubinski J., Debniak T. Vitamin D receptor variants and breast cancer risk in the polish population. Breast Cancer Res. Treat. 2009, 115:629-633.
87. McKay J.D., McCullough M.L., Ziegler R.G., Kraft P., Saltzman B.S., Riboli E., Barricarte A., Berg C.D., Bergland G., Bingham S., Brustad M., Bueno-de-Mesquita H.B., Burdette L., Buring J., Calle E.E., Chanock S.J., Clavel-Chapelon F., Cox D.G., Dossus L., Feigelson H.S., Haiman C.A., Hankinson S.E., Hoover R.N., Hunter D.J., Husing A., Kaaks R., Kolonel L.N., Le Marchand L., Linseisen J., McCarty C.A., Overvad K., Panico S., Purdue M.P., Stram D.O., Stevens V.L., Trichopoulos D., Willett W.C., Yuenger J., Thun M.J. Vitamin D receptor polymorphisms and breast cancer risk: results from the national cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol. Biomarkers Prev. 2009, 18:297-305.
88. Anderson L.N., Cotterchio M., Cole D.E., Knight J.A. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1708-1717.
89. Huang, et al. Relationship between genotypes and haplotypes of vitamin D receptor gene and breast cancer. J. Med. Res. 2012, 41:89-91.
90. Rollison D.E., Cole A.L., Tung K.H., Slattery M.L., Baumgartner K.B., Byers T., Wolff R.K., Giuliano A.R. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res. Treat. 2012, 132:683-691.
91. Fuhrman B.J., Freedman D.M., Bhatti P., Doody M.M., Fu Y.P., Chang S.C., Linet M.S., Sigurdson A.J. Sunlight, polymorphisms of vitamin D-related genes and risk of breast cancer. Anticancer Res. 2013, 33:543-551.
92. Mishra D.K., Wu Y., Sarkissyan M., Sarkissyan S., Chen Z., Shang X., Ong M., Heber D., Koeffler H.P., Vadgama J.V. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women. PLoS One 2013, 8:e57967.
93. Shahbazi S., Alavi S., Majidzadeh-A K., Ghaffarpour M., Soleimani A., Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med. Oncol. 2013, 30:393. 10.1007/s12032-012-0393-7.
94. Speer G., Cseh K., Winkler G., Takacs I., Barna I., Nagy Z., Lakatos P. Oestrogen and vitamin D receptor (VDR) genotypes and the expression of ErbB-2 and EGF receptor in human rectal cancers. Eur. J. Cancer 2001, 37:1463-1468.
95. Park K., Woo M., Nam J., Kim J.C. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Lett. 2006, 237:199-206.
96. Flugge J., Krusekopf S., Goldammer M., Osswald E., Terhalle W., Malzahn U., Roots I. Vitamin D receptor haplotypes protect against development of colorectal cancer. Eur. J. Clin. Pharmacol. 2007, 63:997-1005.
97. Kadiyska T., Yakulov T., Kaneva R., Nedin D., Alexandrova A., Gegova A., Savov A., Mitev V., Kremensky I. Vitamin D and estrogen receptor gene polymorphisms and the risk of colorectal cancer in Bulgaria. Int. J. Colorectal Dis. 2007, 22:395-400.
98. Slattery M.L., Wolff R.K., Herrick J.S., Caan B.J., Potter J.D. IL6 genotypes and colon and rectal cancer. Cancer Causes Control 2007, 18:1095-1105.
99. Li C., Liu Z., Wang L.E., Gershenwald J.E., Lee J.E., Prieto V.G., Duvic M., Grimm E.A., Wei Q. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int. J. Cancer 2008, 122:2077-2084.
100. Parisi E., Rene J.M., Cardus A., Valcheva P., Pinol-Felis C., Valdivielso J.M., Fernandez E. Vitamin D receptor levels in colorectal cancer. Possible role of BsmI polymorphism. J. Steroid Biochem. Mol. Biol. 2008, 111:87-90.
101. Theodoratou E., Farrington S.M., Tenesa A., McNeill G., Cetnarskyj R., Barnetson R.A., Porteous M.E., Dunlop M.G., Campbell H. Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a FokI variant supports a chemoprotective action of vitamin D intake mediated through VDR binding. Int. J. Cancer 2008, 123:2170-2179.
102. Hughes D.J., Hlavata I., Soucek P., Pardini B., Naccarati A., Vodickova L., Jenab M., Vodicka P. Variation in the vitamin D receptor gene is not associated with risk of colorectal cancer in the Czech Republic. J. Gastrointest. Cancer 2011, 42:149-154.
103. Mahmoudi T., Karimi K., Mohebbi S.R., Fatemi S.R., Zali M.R. Start codon FokI and intron 8 BsmI variants in the vitamin D receptor gene and susceptibility to colorectal cancer. Mol. Biol. Rep. 2011, 38:4765-4770.
104. Gunduz M., Cacina C., Toptas B., Yaylim-Eraltan I., Tekand Y., Isbir T. Association of vitamin D receptor gene polymorphisms with colon cancer. Genet. Test. Mol. Biomarkers 2012, 16:1058-1061.
105. Sarkissyan M., Wu Y., Chen Z., Mishra D.K., Sarkissyan S., Giannikopoulos I., Vadgama J.V. Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer 2014, 120:1387-1393.
106. Han J., Colditz G.A., Hunter D.J. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogenesis 2007, 28:390-397.
107. Santonocito C., Capizzi R., Concolino P., Lavieri M.M., Paradisi A., Gentileschi S., Torti E., Rutella S., Rocchetti S., Di Carlo A., Di Stasio E., Ameglio F., Zuppi C., Capoluongo E. Association between cutaneous melanoma, breslow thickness and vitamin D receptor BsmI polymorphism. Br. J. Dermatol. 2007, 156:277-282.
108. Gapska P., Scott R.J., Serrano-Fernandez P., Mirecka A., Rassoud I., Gorski B., Cybulski C., Huzarski T., Byrski T., Nagay L., Maleszka R., Sulikowski M., Lubinski J., Debniak T. Vitamin D receptor variants and the malignant melanoma risk: a population-based study. Cancer. Epidemiol. 2009, 33:103-107.
109. Randerson-Moor J.A., Taylor J.C., Elliott F., Chang Y.M., Beswick S., Kukalizch K., Affleck P., Leake S., Haynes S., Karpavicius B., Marsden J., Gerry E., Bale L., Bertram C., Field H., Barth J.H., Silva Idos S., Swerdlow A., Kanetsky P.A., Barrett J.H., Bishop D.T., Bishop J.A. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. Eur. J. Cancer 2009, 45:3271-3281.
110. Lesiak A., Norval M., Wodz-Naskiewicz K., Pawliczak R., Rogowski-Tylman M., Sysa-Jedrzejowska A., Sobjanek M., Wlodarkiewicz A., Narbutt J. An enhanced risk of basal cell carcinoma is associated with particular polymorphisms in the VDR and MTHFR genes. Exp. Dermatol. 2011, 20:800-804.
111. Lurie G., Wilkens L.R., Thompson P.J., McDuffie K.E., Carney M.E., Terada K.Y., Goodman M.T. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2566-2571.
112. Clendenen T.V., Arslan A.A., Koenig K.L., Enquist K., Wirgin I., Agren A., Lukanova A., Sjodin H., Zeleniuch-Jacquotte A., Shore R.E., Hallmans G., Toniolo P., Lundin E. Vitamin D receptor polymorphisms and risk of epithelial ovarian cancer. Cancer Lett. 2008, 260:209-215.
113. Tworoger S.S., Gates M.A., Lee I.M., Buring J.E., Titus-Ernstoff L., Cramer D., Hankinson S.E. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Cancer Res. 2009, 69:1885-1891.
114. Grant D.J., Hoyo C., Akushevich L., Iversen E.S., Whitaker R., Marks J., Berchuck A., Schildkraut J.M. Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. Gynecol. Oncol. 2013, 129:173-178.
115. Mostowska A., Sajdak S., Pawlik P., Lianeri M., Jagodzinski P.P. Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. Genet. Test. Mol. Biomarkers 2013, 17:183-187.
116. Obara W., Suzuki Y., Kato K., Tanji S., Konda R., Fujioka T. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population. Int. J. Urol. 2007, 14:483-487.
117. Karami S., Brennan P., Hung R.J., Boffetta P., Toro J., Wilson R.T., Zaridze D., Navratilova M., Chatterjee N., Mates D., Janout V., Kollarova H., Bencko V., Szeszenia-Dabrowska N., Holcatova I., Moukeria A., Welch R., Chanock S., Rothman N., Chow W.H., Moore L.E. Vitamin D receptor polymorphisms and renal cancer risk in central and eastern Europe. J. Toxicol. Environ. Health A 2008, 71:367-372.
118. Arjumand W., Ahmad S.T., Seth A., Saini A.K., Sultana S. Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in north Indian population. Tumour Biol. 2012, 33:23-31.
119. Purdue M.P., Hartge P., Davis S., Cerhan J.R., Colt J.S., Cozen W., Severson R.K., Li Y., Chanock S.J., Rothman N., Wang S.S. Sun exposure, vitamin D receptor gene polymorphisms and risk of non-Hodgkin lymphoma. Cancer Causes Control 2007, 18:989-999.
120. Purdue M.P., Lan Q., Kricker A., Vajdic C.M., Rothman N., Armstrong B.K. Vitamin D receptor gene polymorphisms and risk of non-Hodgkin's lymphoma. Haematologica 2007, 92:1145-1146.
121. Smedby K.E., Eloranta S., Duvefelt K., Melbye M., Humphreys K., Hjalgrim H., Chang E.T. Vitamin D receptor genotypes, ultraviolet radiation exposure, and risk of non-Hodgkin lymphoma. Am. J. Epidemiol. 2011, 173:48-54.
122. Anic G.M., Thompson R.C., Nabors L.B., Olson J.J., Browning J.E., Madden M.H., Murtagh F.R., Forsyth P.A., Egan K.M. An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control 2012, 23:1443-1449.
123. Chang C.K., Mulholland H.G., Cantwell M.M., Anderson L.A., Johnston B.T., McKnight A.J., Thompson P.D., Watson R.G., Murray L.J. Vitamin D receptor gene variants and esophageal adenocarcinoma risk: a population-based case-control study. J. Gastrointest. Cancer 2012, 43:512-517. FINBAR study group.
124. Falleti E., Bitetto D., Fabris C., Cussigh A., Fontanini E., Fornasiere E., Fumolo E., Bignulin S., Cmet S., Minisini R., Pirisi M., Toniutto P. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J. Gastroenterol. 2010, 16:3016-3024.
125. Zeljic K., Supic G., Stamenkovic Radak M., Jovic N., Kozomara R., Magic Z. Vitamin D receptor, CYP27B1 and CYP24A1 genes polymorphisms association with oral cancer risk and survival. J. Oral Pathol. Med. 2012, 41:779-787.
126. Penna-Martinez M., Ramos-Lopez E., Stern J., Hinsch N., Hansmann M.L., Selkinski I., Grunwald F., Vorlander C., Wahl R.A., Bechstein W.O., Zeuzem S., Holzer K., Badenhoop K. Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. Thyroid 2009, 19:623-628.
127. Shafia S., Qasim I., Aziz S.A., Bhat I.A., Nisar S., Shah Z.A. Role of vitamin D receptor (VDR) polymorphisms in susceptibility to multiple myeloma in ethnic Kashmiri population. Blood Cells Mol. Dis. 2013, 51:56-60.
128. Li L., Wu B., Yang L., Yin G., Wei W., Sui S., Liu J. Association of vitamin D receptor gene polymorphisms with pancreatic cancer: a pilot study in a north china population. Oncol. Lett. 2013, 5:1731-1735.
129. Huang X., Cao Z., Zhang Z., Yang Y., Wang J., Fang D. No association between vitamin D receptor gene polymorphisms and nasopharyngeal carcinoma in a Chinese Han population. Biosci. Trends 2011, 5:99-103.
130. Dogan I., Onen H.I., Yurdakul A.S., Konac E., Ozturk C., Varol A., Ekmekci A. Polymorphisms in the vitamin D receptor gene and risk of lung cancer. Med. Sci. Monit. 2009, 15:BR232-BR242.